Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study

被引：44

作者：

Napolitano, Maddalena ^{[1
]}

Fabbrocini, Gabriella ^{[2
]}

Neri, Iria ^{[3
]}

Stingeni, Luca ^{[4
]}

Boccaletti, Valeria ^{[5
]}

Piccolo, Vincenzo ^{[6
]}

Amoruso, Giuseppe Fabrizio ^{[7
]}

Malara, Giovanna ^{[8
]}

De Pasquale, Rocco ^{[9
]}

Di Brizzi, Eugenia Veronica ^{[6
]}

Diluvio, Laura ^{[10
]}

Bianchi, Luca ^{[10
]}

Chiricozzi, Andrea ^{[11
,12
]}

Di Guida, Adriana ^{[2
]}

Del Duca, Elisabetta ^{[13
]}

Moschese, Viviana ^{[13
]}

Di Lernia, Vito ^{[14
]}

Dragoni, Federica ^{[15
]}

Gruber, Michaela ^{[16
]}

Hansel, Katharina ^{[4
]}

Licari, Amelia ^{[17
]}

Manti, Sara ^{[18
]}

Leonardi, Salvatore ^{[18
]}

Mastorino, Luca ^{[19
]}

Ortoncelli, Michela ^{[19
]}

Provenzano, Eugenio ^{[7
]}

Palermo, Antonino ^{[20
]}

Patella, Vincenzo ^{[21
]}

Peduto, Tiziana ^{[21
]}

Pezzolo, Elena ^{[22
]}

Piras, Viviana ^{[23
]}

Potestio, Luca ^{[2
]}

Battista, Teresa ^{[2
]}

Satta, Rosanna ^{[24
]}

Termine, Stefania ^{[25
]}

Palma, Paolo ^{[26
]}

Zangari, Paola ^{[26
]}

Patruno, Cataldo ^{[27
]}

机构：

[1] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Campobasso, Italy

[2] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy

[3] Univ Bologna, Div Dermatol, IRCCS Policlin S Orsola, Bologna, Italy

[4] Univ Perugia, Dept Med & Surg, Dermatol Sect, Perugia, Italy

[5] Univ Brescia, Dept Med, Sect Dermatol, Brescia, Italy

[6] Univ Campania Luigi Vanvitelli, Dermatol Unit, Naples, Italy

[7] AO Cosenza, UOC Dermatol, Cosenza, Italy

[8] Grande Osped Metropolitano Bianchi Melacrino More, Struttura Complessa Dermatol, Reggio Di Calabria, Italy

[9] Osped San Marco, UO Dermatol, I-95123 Catania, Italy

[10] Univ Tor Vergata, Syst Med Dept, Dermatol Unit, Policlin Tor Vergata, Rome, Italy

[11] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, UOC Dermatol, Rome, Italy

[12] Univ Cattolica Sacro Cuore, Dipartimento Med & Chirurg Traslaz, Dermatol, Rome, Italy

[13] Univ Roma Tor Vergata, Pediat Immunopathol & Allergol Unit, Policlin Tor Vergata, Viale Oxford 81, Rome, Italy

[14] Arcispedale S Maria Nuova IRCCS, Dermatol Unit, Reggio Emilia, Italy

[15] UOC Dermatol Osped San Donato, Arezzo, Italy

[16] Cent Hosp Bolzano, Dept Pediat, Bolzano, Italy

[17] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Clin Surg Diagnost & Pediat Sci, Pediat Unit, Pavia, Italy

[18] Univ Catania, San Marco Hosp, Dept Clin & Expt Med, Pediat Resp Unit, Catania, Italy

[19] Univ Turin, Dept Clin, Sci, Dermatol Clin, Turin, Italy

[20] Garibaldi Hosp, Dept Pediat, Catania, Italy

[21] Santa Maria Speranza Hosp, Dept Med, Div Allergy & Clin Immunol, I-84091 Battipaglia, Italy

[22] Osped San Bortolo, Dermatol Unit, Vicenza, Italy

[23] AOU Cagliari, Dept Med Sci & Publ Hlth, Dermatol Clin, Cagliari, Italy

[24] Univ Sassari, Dipartimento Sci Med Chirurg & Sperimentali, Sassari, Italy

[25] Santa Chiara Hosp, Div Dermatol, Trento, Italy

[26] Bambino Gesu Pediat Hosp, Acad Dept Pediat DPUO, Res Unit Clin Immunol & Vaccinol, IRCCS, Rome, Italy

[27] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy

来源：

PEDIATRIC DRUGS | 2022年 / 24卷 / 06期

关键词：

SYSTEMIC THERAPIES; GUIDELINES; MANAGEMENT;

D O I：

10.1007/s40272-022-00531-0

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Background The management of paediatric atopic dermatitis (AD) is challenging, mostly relying on emollients and topical corticosteroids. Dupilumab, a fully human monoclonal antibody, has been recently approved for the treatment of children aged 6-11 years with moderate-to-severe AD not adequately controlled with topical therapies or when those therapies are not advisable. Objectives The aim of this study was to evaluate in real life the effectiveness and safety of dupilumab in the treatment of children aged from 6 to 11 years. Methods Demographic and clinical data of children aged 6-11 years, affected by moderate-to-severe AD and treated with dupilumab, were retrospectively collected from 24 dermatological and paediatric referral centres. Dupilumab was administered subcutaneously at an induction dose of 300 mg on day (D) 1, followed by 300 mg on D15 and 300 mg every 4 weeks. Disease severity was assessed at baseline and after week 2 (W2), W4 and W16 of dupilumab therapy using Eczema Area Severity Index (EASI), Pruritus Numerical Rating Scale (P-NRS) and Sleep NRS (S-NRS) and Children's Dermatology Life Quality Index (c-DLQI) score. Results A total of 55 AD children (24 males [43.64%], 31 females [56.36%]; mean age 9.35 +/- 1.75 years) were included. A significant improvement in EASI score, P-NRS, S-NRS and c-DLQI was observed from baseline to W16 of treatment with dupilumab. In particular, at W16 the proportion of patients achieving EASI75 was 74.54%. Moreover, at the same timepoint a significant mean percentage reduction for P-NRS, S-NRS and c-DLQI was also observed (68.39%, 70.22% and 79.03%, respectively). Conclusions Our real-life data seem to confirm the effectiveness of dupilumab in paediatric patients on all disease aspects, including extent and severity of signs, intensity of symptoms, sleep and QoL, with a good safety profile.

引用

页码：671 / 678

页数：8

共 31 条

[1] Counting the Burden: Atopic Dermatitis and Health-related Quality of Life [J].

Ali, Faraz ;

Vyas, Jui ;

Finlay, Andrew Y. .

ACTA DERMATO-VENEREOLOGICA, 2020, 100 :330-340

[2]

[Anonymous], PEDIATR DRUGS

[3] Safety of topical corticosteroids in atopic eczema: an umbrella review [J].

Axon, Emma ;

Chalmers, Joanne R. ;

Santer, Miriam ;

Ridd, Matthew J. ;

Lawton, Sandra ;

Langan, Sinead M. ;

Grindlay, Douglas J. C. ;

Muller, Ingrid ;

Roberts, Amanda ;

Ahmed, Amina ;

Williams, Hywel C. ;

Thomas, Kim S. .

BMJ OPEN, 2021, 11 (07)

[4] Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial [J].

Blauvelt, Andrew ;

de Bruin-Weller, Marjolein ;

Gooderham, Melinda ;

Cather, Jennifer C. ;

Weisman, Jamie ;

Pariser, David ;

Simpson, Eric L. ;

Papp, Kim A. ;

Hong, H. Chih-Ho ;

Rubel, Diana ;

Foley, Peter ;

Prens, Errol ;

Griffiths, Christopher E. M. ;

Etoh, Takafumi ;

Pinto, Pedro Herranz ;

Pujol, Ramon M. ;

Szepietowski, Jacek C. ;

Ettler, Karel ;

Kemeny, Lajos ;

Zhu, Xiaoping ;

Akinlade, Bolanle ;

Hultsch, Thomas ;

Mastey, Vera ;

Gadkari, Abhijit ;

Eckert, Laurent ;

Amin, Nikhil ;

Graham, Neil M. H. ;

Pirozzi, Gianluca ;

Stahl, Neil ;

Yancopoulos, George D. ;

Shumel, Brad .

LANCET, 2017, 389 (10086) :2287-2303

[5] The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease [J].

Brunner, Patrick M. ;

He, Helen ;

Pavel, Ana B. ;

Czarnowicki, Tali ;

Lefferdink, Rachel ;

Erickson, Taylor ;

Canter, Talia ;

Puar, Neha ;

Rangel, Stephanie M. ;

Malik, Kunal ;

Estrada, Yeriel ;

Krueger, James G. ;

Guttman-Yassky, Emma ;

Paller, Amy S. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (02) :510-519

[6]

Colonna C., 2022, J EUR ACAD DERMATOL, V2, P2

[7] Infant sleep and child mental health: a longitudinal investigation [J].

Cook, Fallon ;

Conway, Laura J. ;

Giallo, Rebecca ;

Gartland, Deirdre ;

Sciberras, Emma ;

Brown, Stephanie .

ARCHIVES OF DISEASE IN CHILDHOOD, 2020, 105 (07) :655-660

[8] Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study [J].

Cork, M. J. ;

Thaci, D. ;

Eichenfield, L. F. ;

Arkwright, P. D. ;

Sun, X. ;

Chen, Z. ;

Akinlade, B. ;

Boklage, S. ;

Guillemin, I. ;

Kosloski, M. P. ;

Kamal, M. A. ;

O'Malley, J. T. ;

Patel, N. ;

Graham, N. M. H. ;

Bansal, A. .

BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (05) :857-870

[9] Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE) [J].

de Bruin-Weller, M. ;

Thaci, D. ;

Smith, C. H. ;

Reich, K. ;

Cork, M. J. ;

Radin, A. ;

Zhang, Q. ;

Akinlade, B. ;

Gadkari, A. ;

Eckert, L. ;

Hultsch, T. ;

Chen, Z. ;

Pirozzi, G. ;

Graham, N. M. H. ;

Shumel, B. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) :1083-1101

[10] Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement [J].

Drucker, A. M. ;

Eyerich, K. ;

de Bruin-Weller, M. S. ;

Thyssen, J. P. ;

Spuls, P. I. ;

Irvine, A. D. ;

Girolomoni, G. ;

Dhar, S. ;

Flohr, C. ;

Murrell, D. F. ;

Paller, A. S. ;

Guttman-Yassky, E. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (03) :768-775

← 1 2 3 4 →